For $1.8 million upfront and additional contingent and milestone payments, I-Mab gains full rights to givastomig's parental antibody.

The new space is a free community service meant to help healthcare entrepreneurs connect with potential funders.

As measles cases surge to record levels in the U.S., Health and Human Services Secretary Robert F. | As measles cases surge ...

The United Kingdom is establishing a new biosecurity center designed to improve research into potentially pandemic-causing ...

On May 6, Arcutis reported first-quarter results showed loss of 20 cents a share, which slightly beat estimates. Its sales ...

I-Mab (NASDAQ:IMAB) said on Thursday that it has signed an agreement to acquire Bridge Health Biotech. As part of the deal, I-Mab will provide an initial payment of $1.8M to Bridge Health shareholders ...

Nanochon, a Washington, DC and Baltimore, MD-based orthopedic device biotech company developing an implant for treating articular cartilage defects in the knee, is thrilled to announce that it was ...

Fractyl Health offers a high-risk, high-reward setup with a near-term binary catalyst in the REMAIN-1 cohort data expected Q3 ...

Three young Triangle-based medical technology companies with roots in Duke University research labs are getting major global attention from their industry. They’re among the 65 cutting-edge companies ...

Oscar-winning actress Lupita Nyong’o is sharing about her experience of being diagnosed with uterine fibroids, using the ...

Johannes Fruehauf left Germany for the United States more than 20 years ago to propel his scientific career. But amid ...

UBC Okanagan researchers have developed a 3D bio-printed model that closely mimics the complexity of natural lung tissue, an ...